Drug Trial Radar · NCT06895356
A Study to Assess the Relative Bioavailability of Oral Tavapadon in Healthy Adult Participants
Last checked: Nov 19, 2026Latest source record: Jun 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
83
Actual
Start
Mar 26, 2025
Primary completion
Jun 16, 2025
Study completion Jun 16, 2025
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Mar 26, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study will assess the relative bioavailability of two different Oral formulations of tavapadon in healthy adult participants.
Conditions
- Healthy Volunteer
Interventions
TavapadonDrug
Oral: Tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Experiencing Adverse EventsTime frame: Up to approximately 53 days
- Maximum Observed Plasma Concentration (Cmax) of TavapadonTime frame: Up to approximately 22 days
- Time to Cmax (Tmax) of TavapadonTime frame: Up to approximately 22 days
- Apparent Terminal Phase Elimination Rate Constant (β) of TavapadonTime frame: Up to approximately 22 days
- Terminal Phase Elimination Half-life (t1/2) of TavapadonTime frame: Up to approximately 22 days
- Area Under the Plasma Concentration-time Curve Over the Dosing Interval (AUCτ) of TavapadonTime frame: Up to approximately 22 days
- Area Under the Plasma Concentration-time Curve from Time Zero to Infinity (AUCinf) of TavapadonTime frame: Up to approximately 22 days
- Trough Concentration (Ctrough) of TavapadonTime frame: Up to approximately 22 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Acpru /Id# 275870
Grayslake, Illinois
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.